0001493152-22-026524.txt : 20220922 0001493152-22-026524.hdr.sgml : 20220922 20220922074515 ACCESSION NUMBER: 0001493152-22-026524 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20220922 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220922 DATE AS OF CHANGE: 20220922 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Aesther Healthcare Acquisition Corp. CENTRAL INDEX KEY: 0001869974 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 871309280 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40793 FILM NUMBER: 221257860 BUSINESS ADDRESS: STREET 1: 515 MADISON AVE SUITE 8078 CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646) 908-2658 MAIL ADDRESS: STREET 1: 515 MADISON AVE SUITE 8078 CITY: NEW YORK STATE: NY ZIP: 10022 8-K 1 form8-k.htm
0001869974 false 0001869974 2022-09-21 2022-09-21 0001869974 AEHA:UnitsEachConsistingOfOneClassOrdinaryShareAndOneHalfOfOneRedeemableWarrantMember 2022-09-21 2022-09-21 0001869974 AEHA:ClassOrdinaryShareParValue0.0001PerShareMember 2022-09-21 2022-09-21 0001869974 AEHA:WarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member 2022-09-21 2022-09-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

 

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): September 22, 2022

 

Aesther Healthcare Acquisition Corp.

(Exact name of registrant as specified in its charter)

 

Delaware   001-40793   87-1309280

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

515 Madison Avenue, 8th Floor – Suite 8078

New York, New York

   10022
(Address of principal executive offices)   (Zip Code)

 

(646) 908-2659

(Registrant’s telephone number, including area code)

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Units, each consisting of one Class A Ordinary Share and one half of one Redeemable Warrant   AEHAU   The Nasdaq Stock Market LLC
Class A Ordinary Share, par value $0.0001 per share   AEHA   The Nasdaq Stock Market LLC
Warrants, each warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50   AEHAW   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 7.01 Regulation FD Disclosure.

 

As announced in a press release and related Current Report on Form 8-K dated August 31, 2022, Aesther Healthcare Acquisition Corp., a Delaware corporation (“Aesther”), entered into an Agreement and Plan of Merger by and among Aesther, Aesther Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Aesther (“Merger Sub”), Aesther Healthcare Sponsor, LLC, Aesther’s sponsor (the “Sponsor”), in its capacity as purchaser representative, Ocean Biomedical, Inc., a Delaware corporation (“Ocean Biomedical”), and Dr. Chirinjeev Kathuria, in his capacity as seller representative (as may be amended and/or restated from time to time, the “Merger Agreement”), pursuant to which, among other things, the parties will effect the merger of Merger Sub with and into Ocean Biomedical, with Ocean Biomedical continuing as the surviving entity (the “Merger”), as a result of which all of the issued and outstanding capital stock of Ocean Biomedical shall be exchanged for shares of Class A common stock, par value $0.0001 per share, of Aesther (the “Share Exchange”), subject to the conditions set forth in the Merger Agreement, with Ocean Biomedical surviving the Share Exchange as a wholly-owned subsidiary of Aesther (the Share Exchange and the other transactions contemplated by the Merger Agreement, together, the “Transaction”).

 

On September 22, 2022, Ocean Biomedical and Aesther issued a press release announcing the discovery of a new class of antimalarial drugs which target PfGARP and kill malaria parasites. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

 

Aesther has filed with the U.S. Securities and Exchange Commission (“SEC”) a preliminary proxy statement in connection with the Transaction with Ocean. The preliminary proxy statement contains information about the proposed Transaction, including a business overview of each of Aesther and Ocean, certain terms of the Transaction, pro-forma financial information with respect to each of Aesther and Ocean and risk factors related to the Transaction.

 

Exhibit 99.1 and the information set forth therein and herein shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.

 

Item 8.01 Other Events.

 

The disclosure set forth above in Item 7.01 of this Current Report on Form 8-K is incorporated by reference herein.

 

Forward-Looking Statements

 

This press release contains certain statements that are not historical facts and are forward-looking statements within the meaning of the federal securities laws with respect to the proposed Transaction between Aesther and Ocean Biomedical, including without limitation statements regarding the anticipated benefits of the proposed Transaction, the anticipated timing of the proposed Transaction, the implied enterprise value, future financial condition and performance of Ocean Biomedical and the combined company after the closing and expected financial impacts of the proposed Transaction, the satisfaction of closing conditions to the proposed Transaction, the level of redemptions of Aesther’s public stockholders and the products and markets and expected future performance and market opportunities of Ocean Biomedical. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “think,” “strategy,” “future,” “opportunity,” “potential,” “plan,” “seeks,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.

 

2
 

 

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: (i) the risk that the proposed Transaction may not be completed in a timely manner or at all, which may adversely affect the price of Aesther’s securities; (ii) the risk that the proposed Transaction may not be completed by Aesther’s business combination deadline; (iii) the failure to satisfy the conditions to the consummation of the proposed Transaction, including the approval of the Merger Agreement by the stockholders of Aesther, the satisfaction of the minimum net tangible assets and minimum cash at closing requirements and the receipt of certain governmental, regulatory and third party approvals; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (v) the failure to achieve the minimum amount of cash available following any redemptions by Aesther’s stockholders; (vi) redemptions exceeding anticipated levels or the failure to meet The Nasdaq Global Market’s initial listing standards in connection with the consummation of the proposed Transaction; (vii) the effect of the announcement or pendency of the proposed Transaction on Ocean Biomedical’s business relationships, operating results, and business generally; (viii) risks that the proposed Transaction disrupts current plans and operations of Ocean Biomedical; (ix) the outcome of any legal proceedings that may be instituted against Ocean Biomedical or against Aesther related to the Merger Agreement or the proposed Transaction ; (x) changes in the markets in which Ocean Biomedical’s competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; (xi) changes in domestic and global general economic conditions; (xii) risk that Ocean Biomedical may not be able to execute its growth strategies; (xiii) risks related to the ongoing COVID-19 pandemic and response, including supply chain disruptions; (xiv) risk that Ocean Biomedical may not be able to develop and maintain effective internal controls; (xv) costs related to the proposed Transaction and the failure to realize anticipated benefits of the proposed Transaction or to realize estimated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions; (xvi) the ability to recognize the anticipated benefits of the proposed Transaction and to achieve its commercialization and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Ocean Biomedical to grow and manage growth economically and hire and retain key employees; (xvii) the risk that Ocean Biomedical may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; (xviii) the ability to develop, license or acquire new therapeutics; (xix) the risk that Ocean Biomedical will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (xx) the risk that Ocean Biomedical, post-combination, experiences difficulties in managing its growth and expanding operations; (xxi) the risk of product liability or regulatory lawsuits or proceedings relating to Ocean Biomedical’s business; (xxii) the risk of cyber security or foreign exchange losses; (xxiii) the risk that Ocean Biomedical is unable to secure or protect its intellectual property; and (xxiv) those factors discussed in Aesther’s filings with the SEC and that are contained in the preliminary proxy statement relating to the proposed Transaction and will be contained in the definitive proxy statement relating to the proposed Transaction.

 

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that are described in Aesther’s Annual Report on Form 10-K for the year ended December 31, 2021, and which are described in the “Risk Factors” section of the preliminary proxy statement and the amendments thereto, and will be described in the “Risk Factors” section of the definitive proxy statement, and other documents to be filed by Aesther from time to time with the SEC and which are and will be available at www.sec.gov. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and while Ocean Biomedical and Aesther may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Neither Ocean Biomedical nor Aesther gives any assurance that Ocean Biomedical or Aesther, or the combined company, will achieve its expectations. These forward-looking statements should not be relied upon as representing Aesther’s or Ocean Biomedical’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

 

3
 

 

Additional Information and Where to Find It

 

In connection with the Merger Agreement and the proposed transaction, Aesther has filed with the U.S. Securities and Exchange Commission (the “SEC”) a preliminary proxy statement on Schedule 14A relating to the proposed transaction. This communication is not intended to be, and is not, a substitute for the preliminary proxy statement or any other document that Aesther has filed or may file with the SEC in connection with the proposed transaction. Aesther’s stockholders and other interested persons are advised to read the preliminary proxy statement and the amendments thereto, and, when available, the definitive proxy statement and documents incorporated by reference therein filed in connection with the proposed transaction, as these materials will contain important information about Aesther, Ocean Biomedical, the Merger Agreement, and the proposed transaction. When available, the definitive proxy statement and other relevant materials for the proposed transaction will be mailed to stockholders of Aesther as of a record date to be established for voting on the proposed transaction. Before making any voting or investment decision, investors and stockholders of Aesther are urged to carefully read the entire preliminary proxy statement and definitive proxy statement, when it becomes available, and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, because they will contain important information about the proposed Transaction. Aesther investors and stockholders will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement, and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to: Aesther Healthcare Acquisition Corp., 515 Madison Avenue, Suite 8078, New York, NY 10022, Attention: Mr. Suren Ajjarapu.

 

Participants in the Solicitation

 

Aesther, Ocean Biomedical and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Aesther’s stockholders with respect to the proposed transaction. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed transaction of Aesther’s directors and officers in Aesther’s filings with the SEC, including its most recent Annual Report on Form 10-K, the preliminary proxy statement and the amendments thereto, and when filed with the SEC, the definitive proxy statement, and other documents filed with the SEC. Such information with respect to Ocean Biomedical’s directors and executive officers is also included in the preliminary proxy statement and will be included in the definitive proxy statement.

 

No Offer or Solicitation

 

This press release is not a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction and will not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
99.1   Press release, dated September 22, 2022.
     
104   Cover Page Interactive Data File (embedded with the Inline XBRL)

 

4
 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  AESTHER HEALTHCARE ACQUISITION CORP.
     
  By: /s/ Suren Ajjarapu
  Name: Suren Ajjarapu
  Title: Chief Executive Officer

 

Date: September 22, 2022

 

5

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

 

Aesther Healthcare Acquisition Corp.

 

Building on Their Innovative mRNA Vaccine Program, Ocean Biomedical, Inc. and Aesther Healthcare Acquisition Corp. (NASDAQ: AEHA) Recently Announced Business Combination to Support the Discovery of a New Class of Antimalarial Drugs.

 

  ● Upon closing of their proposed Business Combination, Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition Corp. and will change its name to Ocean Biomedical, Inc., and is expected to be listed on NASDAQ under the symbol, “OCEA”.

 

 

Providence, RI and New York, NY, Sept. 22, 2022. Ocean Biomedical and Aesther Healthcare Acquisition Corp. (“Aesther”) (NASDAQ: AEHA) recently announced business combination, once closed, will further Ocean Biomedical’s work on the discovery of a whole new class of antimalarial drugs which target PfGARP and kill malaria parasites.

 

In recent studies published and reviewed in Nature, Ocean Biomedical’s Scientific Co-founder, Dr. Jake Kurtis, identified the parasite protein PfGARP as a target of human antibodies which kill up to 100% of parasites in vitro by inducing apoptosis or parasite programmed cell death – this discovery forms the basis of Ocean Biomedical’s lipid encapsulated mRNA-based vaccine and therapeutic monoclonal antibodies.

 

Ocean’s breakthrough approach targets the blood-stage portion of the malaria lifecycle – the stage responsible for all clinical disease and death, and therefore has the potential of significantly greater efficacy compared with vaccines targeting other stages.

 

Now, Dr. Kurtis’ team has developed a family of small molecule drugs which bind to PfGARP at nanomolar concentrations and kill parasites by inducing apoptosis. They have demonstrated these drugs: 1) are highly specific for PfGARP binding, 2) are non-toxic in multiple in vitro and in vivo systems, 3) have excellent pharmacokinetic properties, and 4) rapidly clear parasitemia in animal models. Ocean Biomedical and Aesther Healthcare are proud to add this significant program to our pipeline.

 

Malaria caused by infection with Plasmodium parasites is the greatest single-agent killer of children on the planet, killing approximately 627,000 individuals last year. Artemisinin-based drug therapy remains the mainstay of treatment, but the spread of parasites resistant to this family of compounds threatens recent progress achieved by antimalarial campaigns and underscores the urgent need to identify new anti-malarial drugs. Surprisingly, WHO malaria treatment protocols do not reserve novel classes of antimalarials specifically for the treatment of severe malaria- a central tenet of antimicrobial stewardship- due to the paucity of available alternative drug classes.

 

 
 

 

“Small molecule drugs targeting PfGARP have an impressive ability to induce parasite cell death and represent a novel class of anti-malarials, which we so desperately need as artemisinin resistant parasites spread,” commented Dr. Jake Kurtis, Chair of Pathology and Laboratory Medicine at the Warren Alpert Medical School Brown University; Scientific co-founder.

 

“Falciparum malaria is a leading cause of death in children world-wide and our global malaria treatment strategy relies almost exclusively on artemisinin-based drugs. The recent emergence of high grade resistance to artemisinin is an existential threat to this strategy and mandates the development of novel classes of antimalarials. We are thrilled to announce our discovery of a novel class of antimalarials which have to potential to save hundreds of thousands of lives “ said Dr. Chirinjeev Kathuria, co-founder and Executive Chairman.

 

Suren Ajjarapu, Chairman and CEO of Aesther, commented, “Aesther is honored to be part of the exciting discovery announced by Ocean Biomedical today. We look forward to working with Ocean to bring these therapies to patients. This discovery, coupled with the powerful approach in our malaria vaccine program, will lead to long term shareholder value growth and appreciation.”

 

About Aesther Healthcare Acquisition Corp.

 

Aesther is a special purpose acquisition company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. Its principals possess public and private market investing experience and operational knowledge to bring value added benefits to Ocean Biomedical. The Aesther team has substantial experience investing in and operating businesses in multiple sectors, as well as a significant long-term track record in creatively structuring transactions to unlock and maximize value.

 

To learn more, visit www.aestherhealthcarespac.com.

 

About Ocean Biomedical

 

Ocean Biomedical, Inc. is a Providence, Rhode Island-based biopharma company with an innovative business model that accelerates the development and commercialization of scientifically compelling assets from research universities and medical centers. Ocean Biomedical deploys the funding and expertise to move new therapeutic candidates efficiently from the laboratory to the clinic, to the world. Ocean Biomedical is currently developing five promising discoveries that have the potential to achieve life-changing outcomes in lung cancer, brain cancer, pulmonary fibrosis, and the prevention and treatment of malaria. The Ocean Biomedical team is working on solving some of the world’s toughest problems, for the people who need it most.

 

To learn more, visit www.oceanbiomedical.com

 

 
 

 

Forward-Looking Statements

 

This press release contains certain statements that are not historical facts and are forward-looking statements within the meaning of the federal securities laws with respect to the merger agreement (“Merger Agreement”) between Aesther and Ocean Biomedical and the proposed merger contemplated thereby (the “Transaction”), including without limitation statements regarding the anticipated benefits of the proposed Transaction, the anticipated timing of the proposed Transaction, the implied enterprise value, future financial condition and performance of Ocean Biomedical and the combined company after the closing and expected financial impacts of the proposed Transaction, the satisfaction of closing conditions to the proposed Transaction, the level of redemptions of Aesther’s public stockholders and the products and markets and expected future performance and market opportunities of Ocean Biomedical. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “think,” “strategy,” “future,” “opportunity,” “potential,” “plan,” “seeks,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties.

 

The announcement today is based solely on laboratory and animal studies. Ocean Biomedical has not conducted any studies that show similar efficacy or safety in humans. There can be no assurances that this treatment will prove safe or effective in humans, and that any clinical benefits of this treatment is subject to clinical trials and ultimate approval of its use in patients by the FDA. Such approval, if granted, could be years away.

 

These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: (i) the risk that the proposed Transaction may not be completed in a timely manner or at all, which may adversely affect the price of Aesther’s securities; (ii) the risk that the proposed Transaction may not be completed by Aesther’s business combination deadline; (iii) the failure to satisfy the conditions to the consummation of the proposed Transaction, including the approval of the Merger Agreement by the stockholders of Aesther, the satisfaction of the minimum net tangible assets and minimum cash at closing requirements and the receipt of certain governmental, regulatory and third party approvals; (iv) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (v) the failure to achieve the minimum amount of cash available following any redemptions by Aesther’s stockholders; (vi) redemptions exceeding anticipated levels or the failure to meet The Nasdaq Global Market’s initial listing standards in connection with the consummation of the proposed Transaction; (vii) the effect of the announcement or pendency of the proposed Transaction on Ocean Biomedical’s business relationships, operating results, and business generally; (viii) risks that the proposed Transaction disrupts current plans and operations of Ocean Biomedical; (ix) the outcome of any legal proceedings that may be instituted against Ocean Biomedical or against Aesther related to the Merger Agreement or the proposed Transaction ; (x) changes in the markets in which Ocean Biomedical’s competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; (xi) changes in domestic and global general economic conditions; (xii) risk that Ocean Biomedical may not be able to execute its growth strategies; (xiii) risks related to the ongoing COVID-19 pandemic and response, including supply chain disruptions; (xiv) risk that Ocean Biomedical may not be able to develop and maintain effective internal controls; (xv) costs related to the proposed Transaction and the failure to realize anticipated benefits of the proposed Transaction or to realize estimated pro forma results and underlying assumptions, including with respect to estimated stockholder redemptions; (xvi) the ability to recognize the anticipated benefits of the proposed Transaction and to achieve its commercialization and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Ocean Biomedical to grow and manage growth economically and hire and retain key employees; (xvii) the risk that Ocean Biomedical may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; (xviii) the ability to develop, license or acquire new therapeutics; (xix) the risk that Ocean Biomedical will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; (xx) the risk that Ocean Biomedical, post-combination, experiences difficulties in managing its growth and expanding operations; (xxi) the risk of product liability or regulatory lawsuits or proceedings relating to Ocean Biomedical’s business; (xxii) the risk of cyber security or foreign exchange losses; (xxiii) the risk that Ocean Biomedical is unable to secure or protect its intellectual property; and (xxiv) those factors discussed in Aesther’s filings with the SEC and that that will be contained in the proxy statement relating to the proposed Transaction .

 

 
 

 

The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that are described in the “Risk Factors” section of the preliminary proxy statement and the amendments thereto, and will be described in the definitive proxy statement, and other documents to be filed by Aesther from time to time with the SEC and which, as applicable, are or will be available at www.sec.gov. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and while Ocean Biomedical and Aesther may elect to update these forward-looking statements at some point in the future, they assume no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. Neither Ocean Biomedical nor Aesther gives any assurance that Ocean Biomedical or Aesther, or the combined company, will achieve its expectations. These forward-looking statements should not be relied upon as representing Aesther’s or Ocean Biomedical’s assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

 

Additional Information and Where to Find It

 

In connection with the Merger Agreement and the proposed Transaction, Aesther has filed with the U.S. Securities and Exchange Commission (the “SEC”) a preliminary proxy statement on Schedule 14A relating to the proposed Transaction. This communication is not intended to be, and is not, a substitute for the preliminary proxy statement or any other document that Aesther has filed or may file with the SEC in connection with the proposed Transaction. Aesther’s stockholders and other interested persons are advised to read, when available, the preliminary proxy statement and the amendments thereto, the definitive proxy statement and documents incorporated by reference therein filed in connection with the proposed Transaction, as these materials will contain important information about Aesther, Ocean Biomedical, the Merger Agreement, and the proposed Transaction. When available, the definitive proxy statement and other relevant materials for the proposed Transaction will be mailed to stockholders of Aesther as of a record date to be established for voting on the proposed Transaction. Before making any voting or investment decision, investors and stockholders of Aesther are urged to carefully read the entire proxy statement, when they become available, and any other relevant documents filed with the SEC, as well as any amendments or supplements to these documents, because they will contain important information about the proposed Transaction. Aesther investors and stockholders will also be able to obtain copies of the preliminary proxy statement, the definitive proxy statement, and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC’s website at www.sec.gov, or by directing a request to: Aesther Healthcare Acquisition Corp., 515 Madison Avenue, Suite 8078, New York, NY 10022, Attention: Mr. Suren Ajjarapu.

 

Participants in the Solicitation

 

Aesther, Ocean Biomedical and their respective directors, executive officers, other members of management and employees may be deemed participants in the solicitation of proxies from Aesther’s stockholders with respect to the proposed Transaction. Investors and security holders may obtain more detailed information regarding the names and interests in the proposed Transaction of Aesther’s directors and officers in Aesther’s filings with the SEC, including, its Annual Report on From 10-K for the year ended December 31, 2021,the preliminary proxy statement and the amendments thereto, when filed with the SEC, the definitive proxy statement, and other documents filed with the SEC.

 

No Offer or Solicitation

 

This press release is not a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed Transaction and will not constitute an offer to sell or the solicitation of an offer to buy any securities, nor will there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

 

Investor Contact

 

IR@aestherhealthcarespac.com

 

Ocean Biomedical Media Relations

 

Kevin Kertscher

Communications Director

kkertscher@oceanbiomedical.com

 

 

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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ex99-1_002.jpg begin 644 ex99-1_002.jpg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end EX-101.SCH 5 aeha-20220921.xsd INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 6 aeha-20220921_def.xml INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 7 aeha-20220921_lab.xml INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Class of Stock [Axis] Units, each consisting of one Class A Ordinary Share and one half of one Redeemable Warrant Class A Ordinary Share, par value $0.0001 per share Warrants, each warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 Statement [Table] Statement [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 8 aeha-20220921_pre.xml INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Sep. 21, 2022
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 22, 2022
Entity File Number 001-40793
Entity Registrant Name Aesther Healthcare Acquisition Corp.
Entity Central Index Key 0001869974
Entity Tax Identification Number 87-1309280
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 515 Madison Avenue
Entity Address, Address Line Two 8th Floor – Suite 8078
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10022
City Area Code (646)
Local Phone Number 908-2659
Written Communications false
Soliciting Material true
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Units, each consisting of one Class A Ordinary Share and one half of one Redeemable Warrant  
Title of 12(b) Security Units, each consisting of one Class A Ordinary Share and one half of one Redeemable Warrant
Trading Symbol AEHAU
Security Exchange Name NASDAQ
Class A Ordinary Share, par value $0.0001 per share  
Title of 12(b) Security Class A Ordinary Share, par value $0.0001 per share
Trading Symbol AEHA
Security Exchange Name NASDAQ
Warrants, each warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50  
Title of 12(b) Security Warrants, each warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50
Trading Symbol AEHAW
Security Exchange Name NASDAQ
XML 10 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001869974 2022-09-21 2022-09-21 0001869974 AEHA:UnitsEachConsistingOfOneClassOrdinaryShareAndOneHalfOfOneRedeemableWarrantMember 2022-09-21 2022-09-21 0001869974 AEHA:ClassOrdinaryShareParValue0.0001PerShareMember 2022-09-21 2022-09-21 0001869974 AEHA:WarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member 2022-09-21 2022-09-21 iso4217:USD shares iso4217:USD shares 0001869974 false 8-K 2022-09-22 Aesther Healthcare Acquisition Corp. DE 001-40793 87-1309280 515 Madison Avenue 8th Floor – Suite 8078 New York NY 10022 (646) 908-2659 false true false false Units, each consisting of one Class A Ordinary Share and one half of one Redeemable Warrant AEHAU NASDAQ Class A Ordinary Share, par value $0.0001 per share AEHA NASDAQ Warrants, each warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 AEHAW NASDAQ true false EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 4 24 1 false 3 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://aestherhealthcarespac.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm aeha-20220921.xsd aeha-20220921_def.xml aeha-20220921_lab.xml aeha-20220921_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2022 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 1, "contextCount": 4, "dts": { "definitionLink": { "local": [ "aeha-20220921_def.xml" ] }, "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "aeha-20220921_lab.xml" ] }, "presentationLink": { "local": [ "aeha-20220921_pre.xml" ] }, "schema": { "local": [ "aeha-20220921.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 66, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 3, "memberStandard": 0, "nsprefix": "AEHA", "nsuri": "http://aestherhealthcarespac.com/20220921", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-09-21to2022-09-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://aestherhealthcarespac.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2022-09-21to2022-09-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 3, "tag": { "AEHA_ClassOrdinaryShareParValue0.0001PerShareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class A Ordinary Share, par value $0.0001 per share" } } }, "localname": "ClassOrdinaryShareParValue0.0001PerShareMember", "nsuri": "http://aestherhealthcarespac.com/20220921", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "domainItemType" }, "AEHA_UnitsEachConsistingOfOneClassOrdinaryShareAndOneHalfOfOneRedeemableWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Units, each consisting of one Class A Ordinary Share and one half of one Redeemable Warrant" } } }, "localname": "UnitsEachConsistingOfOneClassOrdinaryShareAndOneHalfOfOneRedeemableWarrantMember", "nsuri": "http://aestherhealthcarespac.com/20220921", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "domainItemType" }, "AEHA_WarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Warrants, each warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50" } } }, "localname": "WarrantsEachWarrantExercisableForOneClassOrdinaryShareAtExercisePriceOf11.50Member", "nsuri": "http://aestherhealthcarespac.com/20220921", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [], "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "domainItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://aestherhealthcarespac.com/role/Cover" ], "xbrltype": "stringItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 17 0001493152-22-026524-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-026524-xbrl.zip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end